In the wake of the COVID-19 pandemic, Chinese pharmaceutical companies are researching and developing vaccines with standardized processes, strictly following the scientific rules in place. The regulators concerned have said the inactivated vaccines produced by Chinese companies are safe and effective. The technology of inactive vaccine is mature and has been used in many other vaccines. The transport of the inactivated vaccines does not require ultralow cold chain logistics.
More than 10 BRI countries, including the United Arab Emirates, Indonesia, Pakistan, Turkey, Brazil, Egypt, Laos, Cambodia, the Philippines, and Bahrain, have been using Chinese vaccines already. More countries have signed vaccine procurement contracts with China.
At the request of the World Health Organization, China has decided to provide 10 million COVID-19 vaccine doses to COVAX, in order to meet the urgent needs of developing countries. Based on the BRI cooperation platform, China will offer more vaccine support to more countries, to strengthen efforts toward eradicating the disease.